| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
50 |
| Employees |
12 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-38 |
| Cash Flow (TTM) (Millions $) |
-27 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Zynerba Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing and commercializing transdermal cannabinoid therapies for various medical conditions. The company focuses on developing innovative treatments for patients who have limited options or who may not have responded well to other therapies. Zynerba's proprietary technology allows for the delivery of cannabinoids through the skin, offering advantages such as precise dosing and continuous drug delivery. The company's lead product candidate is Zygel, which is being developed for the treatment of Fragile X syndrome, Autism spectrum disorder, 22q11.2 Deletion Syndrome, and other neuropsychiatric disorders. Zynerba Pharmaceuticals aims to improve the lives of patients by providing effective, convenient, and safe cannabinoid-based therapies.
Company Address: 80 W. Lancaster Avenue Devon 19333 PA
Company Phone Number: 581-7505 Stock Exchange / Ticker: NASDAQ ZYNE
|
%
0.44%